NFKB1 and plasma cell myeloma: Further, in vitro and in vivo investigations of TAS4464 in multiple myeloma models found that the antitumor activity of TAS4464 occurs through inhibition of nuclear factor κB (NFκB) activation, thereby affecting the canonical and noncanonical NFκB pathways [14].